Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analysis of the molecular mechanism by which Oba01 combined with Abemaciclib kills colorectal cancer organoids

ABSTRACT: Proteomics reveals the molecular mechanism by which the antibody-drug conjugate Oba01 and the CDK4/6 inhibitor Abemaciclib jointly kill colorectal cancer organoids

ORGANISM(S): Homo Sapiens

SUBMITTER: Shuyong Zhang

PROVIDER: PXD063685 | iProX | Thu May 01 00:00:00 BST 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Proteomics analysis of the molecular mechanism by which Antibody-drug conjugate Oba01 combined with Abemaciclib kills colorectal cancer organoids

Project description:Proteomics reveals the molecular mechanism by which the antibody-drug conjugate Oba01 and the CDK4/6 inhibitor Abemaciclib jointly kill colorectal cancer organoids

2025-05-03 | PXD063571 | JPOST Repository

DIA analysis of colorectal cancer organoids

Project description:The goal of this project was to characterize the proteome and phosphoproteome of colorectal cancer organoids.

2023-12-10 | PXD018913 | Pride

DIA analysis of colorectal cancer organoids

Project description:The goal of this project was to characterize the proteome of colorectal cancer organoids from different patients.

2023-11-16 | PXD019124 | Pride

Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS

Project description:As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorectal cancer organoids by LC-QTOF-MS facing the challenge of capturing metabolic information from minimal sample amount (< 500 cells/injection) in the presence of extracellular matrix (ECM). The best procedure of the tested protocols included ultrasonic metabolite extraction with acetonitrile/methanol/water (2:2:1, v/v/v) without ECM removal. To eliminate ECM-derived background signals, we implemented a data filtering procedure based on p-value and fold change cut-offs which retained features with signal intensities >120% compared to matrix-derived signals present in blank samples. As a proof-of-concept, the method was applied to examine the early metabolic response of colorectal cancer organoids to 5-fluorouracil treatment. Statistical analysis revealed dose-dependent changes in the metabolic profiles of treated organoids including elevated levels of 2'-deoxyuridine, 2'-O-methylcytidin, inosine and 1-methyladenosine and depletion of 2'-deoxyadenosine and specific phospholipids. In accordance with the mechanism of action of 5-fluorouracil, changed metabolites are mainly involved in purine and pyrimidine metabolism. The novel protocol provides a first basis for the assessment of metabolic drug response phenotypes in 3D organoid models.

2021-10-12 | MTBLS2130 | MetaboLights

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

Project description:The heat-shock protein 90 (HSP90) is a promising target in cancer therapy, but its inhibitors' clinical trial failures are partly due to a compensatory heat-shock response (HSR) mediated by heat-shock factor 1 (HSF1). We previously showed that wildtype p53 reduces HSR by repressing HSF1 via a p21-CDK4/6-MAPK-HSF1 axis. Here, we explore if simultaneous p53 activation or cell cycle inhibition can disrupt the HSF1-HSR axis and enhance HSP90 inhibitors' efficiency. mRNA sequencing was performed on HCT116 cells treated for 24 hours with DMSO, 50 nM Ganetespib, 1 µM RG-7388, or their combination. We found that the p53 activator Idasanutlin suppresses HSF1-HSR activity in HSP90 inhibitor-based therapies, synergistically reducing cell viability and accelerating cell death in p53-proficient colorectal cancer (CRC) cells and organoids. Combination therapy upregulates p53 pathways, apoptosis, and inflammation. In a CRC mouse model, dual HSF1-HSP90 inhibition represses tumor growth and alters immune cell composition. CDK4/6 inhibition under HSP90 inhibition mimics HSR repression in p53-proficient CRC cells. In p53-deficient CRC cells and p53-mutated organoids, combined HSP90 and CDK4/6 inhibition suppresses HSF1-HSR and reduces cancer growth, offering a p53-independent strategy for CRC treatment. In conclusion, we present new options to improve HSP90-based therapies for enhanced CRC treatment.

2025-03-28 | E-MTAB-14877 | biostudies-arrayexpress

RNAseq of colorectal cancer organoids

Project description:RNAseq of colorectal cancer organoids

| PRJNA904315 | ENA

Building a spectral library to analyze colorectal cancer organoids

Project description:The goal of this project was to build SWATH Spectral libraries to analyze colorectal cancer organoids.

2023-12-10 | PXD018835 | Pride

DIA analysis of colorectal cancer organoids (cancer vs metastasis)

Project description:The goal of this project was to characterize the proteome of colorectal cancer organoids from a metastatic and original tumor.

2023-12-10 | PXD018922 | Pride

Building spectral libraries to analyze phosphopeptides in colorectal cancer organoids

Project description:The goal of this project was to build SWATH Spectral libraries to analyze phosphopeptides from colorectal cancer organoids.

2023-12-10 | PXD018862 | Pride

Expression data of cultured organoids derived from human colorectal cancer.

Project description:We analyzed gene expression of 3 lines of patient-derived colorectal cancer organoids.

2022-01-05 | GSE184732 | GEO